|

CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib) Clinical Trials

1 actively recruiting trial

Also known as: We will then evaluate the effects of CDK4/6 inhibitors on the selected MB PDOs.

Pipeline

Early 1: 1

Top Sponsors

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS1

Indications

  • Medulloblastoma, Childhood1
  • Cancer1

Other1 trial

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.